415 related articles for article (PubMed ID: 21270186)
1. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
[TBL] [Abstract][Full Text] [Related]
2. Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes.
Besser RE; Shields BM; Hammersley SE; Colclough K; McDonald TJ; Gray Z; Heywood JJ; Barrett TG; Hattersley AT
Pediatr Diabetes; 2013 May; 14(3):181-8. PubMed ID: 23289766
[TBL] [Abstract][Full Text] [Related]
3. Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus.
Ozsu E; Cizmecioglu FM; Yesiltepe Mutlu G; Yuksel AB; Calıskan M; Yesilyurt A; Hatun S
Horm Res Paediatr; 2018; 90(4):257-265. PubMed ID: 30481753
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of Urinary C-Peptide Creatinine Ratio in Patients with Different Types of Diabetes.
Wang Y; Gao Y; Cai X; Chen L; Zhou L; Ma Y; Gong S; Han X; Ji L
J Diabetes Res; 2019; 2019():1747684. PubMed ID: 31485449
[TBL] [Abstract][Full Text] [Related]
5. Urinary C-peptide creatinine ratio to differentiate type 2 diabetes mellitus from type 1 in pediatric patients.
Elzahar W; Arafa A; Youssef A; Erfan A; El Amrousy D
Eur J Pediatr; 2020 Jul; 179(7):1115-1120. PubMed ID: 32052124
[TBL] [Abstract][Full Text] [Related]
6. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.
Thanabalasingham G; Pal A; Selwood MP; Dudley C; Fisher K; Bingley PJ; Ellard S; Farmer AJ; McCarthy MI; Owen KR
Diabetes Care; 2012 Jun; 35(6):1206-12. PubMed ID: 22432108
[TBL] [Abstract][Full Text] [Related]
7. Urinary C-Peptide/Creatinine Ratio Can Distinguish Maturity-Onset Diabetes of the Young from Type 1 Diabetes in Children and Adolescents: A Single-Center Experience.
Yılmaz Agladioglu S; Sagsak E; Aycan Z
Horm Res Paediatr; 2015; 84(1):54-61. PubMed ID: 25792383
[TBL] [Abstract][Full Text] [Related]
8. Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients.
Shields BM; Shepherd M; Hudson M; McDonald TJ; Colclough K; Peters J; Knight B; Hyde C; Ellard S; Pearson ER; Hattersley AT;
Diabetes Care; 2017 Aug; 40(8):1017-1025. PubMed ID: 28701371
[TBL] [Abstract][Full Text] [Related]
9. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
[TBL] [Abstract][Full Text] [Related]
10. Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young.
Kyithar MP; Bonner C; Bacon S; Kilbride SM; Schmid J; Graf R; Prehn JH; Byrne MM
J Transl Med; 2013 Jun; 11():156. PubMed ID: 23803251
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young.
Ellard S; Colclough K
Hum Mutat; 2006 Sep; 27(9):854-69. PubMed ID: 16917892
[TBL] [Abstract][Full Text] [Related]
12. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
[TBL] [Abstract][Full Text] [Related]
13. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
Thanabalasingham G; Shah N; Vaxillaire M; Hansen T; Tuomi T; Gašperíková D; Szopa M; Tjora E; James TJ; Kokko P; Loiseleur F; Andersson E; Gaget S; Isomaa B; Nowak N; Raeder H; Stanik J; Njolstad PR; Malecki MT; Klimes I; Groop L; Pedersen O; Froguel P; McCarthy MI; Gloyn AL; Owen KR
Diabetologia; 2011 Nov; 54(11):2801-10. PubMed ID: 21814873
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth.
Pihoker C; Gilliam LK; Ellard S; Dabelea D; Davis C; Dolan LM; Greenbaum CJ; Imperatore G; Lawrence JM; Marcovina SM; Mayer-Davis E; Rodriguez BL; Steck AK; Williams DE; Hattersley AT;
J Clin Endocrinol Metab; 2013 Oct; 98(10):4055-62. PubMed ID: 23771925
[TBL] [Abstract][Full Text] [Related]
15. Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes.
Shepherd M; Shields B; Hammersley S; Hudson M; McDonald TJ; Colclough K; Oram RA; Knight B; Hyde C; Cox J; Mallam K; Moudiotis C; Smith R; Fraser B; Robertson S; Greene S; Ellard S; Pearson ER; Hattersley AT;
Diabetes Care; 2016 Nov; 39(11):1879-1888. PubMed ID: 27271189
[TBL] [Abstract][Full Text] [Related]
16. Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of Chinese patients with maturity-onset diabetes of the young.
Wang X; Wang T; Yu M; Zhang H; Ping F; Zhang Q; Xu J; Feng K; Xiao X
Acta Diabetol; 2019 Mar; 56(3):281-288. PubMed ID: 30293189
[TBL] [Abstract][Full Text] [Related]
17. Mutations in HNF1A result in marked alterations of plasma glycan profile.
Thanabalasingham G; Huffman JE; Kattla JJ; Novokmet M; Rudan I; Gloyn AL; Hayward C; Adamczyk B; Reynolds RM; Muzinic A; Hassanali N; Pucic M; Bennett AJ; Essafi A; Polasek O; Mughal SA; Redzic I; Primorac D; Zgaga L; Kolcic I; Hansen T; Gasperikova D; Tjora E; Strachan MW; Nielsen T; Stanik J; Klimes I; Pedersen OB; Njølstad PR; Wild SH; Gyllensten U; Gornik O; Wilson JF; Hastie ND; Campbell H; McCarthy MI; Rudd PM; Owen KR; Lauc G; Wright AF
Diabetes; 2013 Apr; 62(4):1329-37. PubMed ID: 23274891
[TBL] [Abstract][Full Text] [Related]
18. Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection.
Ekholm E; Shaat N; Holst JJ
Acta Diabetol; 2012 Oct; 49(5):349-54. PubMed ID: 21761282
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
Mughal SA; Park R; Nowak N; Gloyn AL; Karpe F; Matile H; Malecki MT; McCarthy MI; Stoffel M; Owen KR
Diabet Med; 2013 Feb; 30(2):246-50. PubMed ID: 23157689
[TBL] [Abstract][Full Text] [Related]
20. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
Kyithar MP; Bacon S; Pannu KK; Rizvi SR; Colclough K; Ellard S; Byrne MM
Diabetes Metab; 2011 Dec; 37(6):512-9. PubMed ID: 21683639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
